Get started
Work

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan Conditioning for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Year: 2012
Type: article
Study design: Clinical Trial
Abstract: High-dose chemotherapy followed by autologous HCT is a preferred primary treatment approach in multiple myeloma. In this study, we examine the effects of adding bortezomib to standard high-dose melphalan in patients with newly diagnosed, chemosensitive myeloma.
DOI: 10.1016/j.bbmt.2011.12.241
Authors: T. Nishihori, J.L. Ochoa-Bayona, J. Pidala, K. Shain, R. Baz, C.M. Simonelli, D. Sullivan, C. Anasetti, M. Alsina
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2108124109
FWCI:
Cites:
Cited by:
Related to: 10